Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Kestra Private Wealth Services LLC

Kestra Private Wealth Services LLC trimmed its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 49.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 9,314 shares of the biopharmaceutical company’s stock after selling 9,161 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Halozyme Therapeutics were worth $445,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the stock. Heck Capital Advisors LLC purchased a new position in shares of Halozyme Therapeutics during the fourth quarter valued at $29,000. Toth Financial Advisory Corp purchased a new position in shares of Halozyme Therapeutics during the third quarter valued at $57,000. FSC Wealth Advisors LLC purchased a new position in shares of Halozyme Therapeutics during the third quarter valued at $65,000. CWM LLC grew its holdings in shares of Halozyme Therapeutics by 77.5% during the third quarter. CWM LLC now owns 1,530 shares of the biopharmaceutical company’s stock valued at $88,000 after buying an additional 668 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its holdings in shares of Halozyme Therapeutics by 173.6% during the third quarter. Farther Finance Advisors LLC now owns 1,620 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 1,028 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the transaction, the director now owns 38,611 shares of the company’s stock, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $58.29 on Monday. Halozyme Therapeutics, Inc. has a fifty-two week low of $35.23 and a fifty-two week high of $65.53. The business has a 50-day moving average of $52.50 and a two-hundred day moving average of $54.49. The stock has a market capitalization of $7.42 billion, a P/E ratio of 19.30, a P/E/G ratio of 0.44 and a beta of 1.25. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. JMP Securities lifted their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Piper Sandler lifted their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. HC Wainwright reissued a “buy” rating and set a $70.00 price objective on shares of Halozyme Therapeutics in a research report on Tuesday, February 4th. Finally, Wells Fargo & Company reduced their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $60.89.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.